Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 2
2006 7
2007 3
2008 5
2009 10
2010 4
2011 5
2012 4
2013 11
2014 6
2015 8
2016 8
2017 9
2018 11
2019 9
2020 10
2021 12
2022 7
2023 3
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Nonparametric Testing Under Randomized Sketching.
Liu M, Shang Z, Yang Y, Cheng G. Liu M, et al. Among authors: cheng g. IEEE Trans Pattern Anal Mach Intell. 2022 Aug;44(8):4280-4290. doi: 10.1109/TPAMI.2021.3063223. Epub 2022 Jul 4. IEEE Trans Pattern Anal Mach Intell. 2022. PMID: 33656986
The "double-edged sword effect" of nicotine.
Liu Y, Cheng G, Cao J, Zhang J, Luo C, Huang L. Liu Y, et al. Among authors: cheng g. Fitoterapia. 2024 Sep;177:106102. doi: 10.1016/j.fitote.2024.106102. Epub 2024 Jun 28. Fitoterapia. 2024. PMID: 38945494 Review.
Immune-related gene expression signatures in colorectal cancer.
Sun Z, Xia W, Lyu Y, Song Y, Wang M, Zhang R, Sui G, Li Z, Song L, Wu C, Liew CC, Yu L, Cheng G, Cheng C. Sun Z, et al. Among authors: cheng g. Oncol Lett. 2021 Jul;22(1):543. doi: 10.3892/ol.2021.12804. Epub 2021 May 20. Oncol Lett. 2021. PMID: 34079596 Free PMC article.
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer.
Xing P, Wang S, Bi M, Liu Y, Zeng J, Wang X, Xiao K, Li W, Guo J, Wang P, Pan Y, Ren B, Gao E, Zhang L, Wang Y, Gan T, Cheng G, Shi Y. Xing P, et al. Among authors: cheng g. EClinicalMedicine. 2024 Sep 3;75:102791. doi: 10.1016/j.eclinm.2024.102791. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39286636 Free PMC article.
131 results